4.01
price down icon5.20%   -0.22
after-market 시간 외 거래: 4.20 0.19 +4.74%
loading

Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스

pulisher
Mar 28, 2025

JSPR stock touches 52-week low at $4.54 amid market challenges By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

JSPR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia

Mar 28, 2025
pulisher
Mar 26, 2025

Jasper Therapeutics Inc Files For Common Stock Offering Of Up To $100 MillionSEC Filing - MarketScreener

Mar 26, 2025
pulisher
Mar 25, 2025

DBV Technologies (NASDAQ:DBVT) vs. Jasper Therapeutics (NASDAQ:JSPR) Head to Head Comparison - Defense World

Mar 25, 2025
pulisher
Mar 20, 2025

Jasper Therapeutics inks new sales agreement, ends previous deal By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $62.50 - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Jasper Therapeutics inks new sales agreement, ends previous deal - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Jasper Therapeutics Files $300 Million Mixed Shelf -March 19, 2025 at 05:08 pm EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Jasper Therapeutics Signs New Sales Agreement with Jefferies - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Jasper Therapeutics terminates Cantor sales agreement -March 19, 2025 at 04:53 pm EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Jasper Therapeutics files for mixed shelf offering of up to $300 mln -March 19, 2025 at 04:17 pm EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 14, 2025

(JSPR) On The My Stocks Page - news.stocktradersdaily.com

Mar 14, 2025
pulisher
Mar 14, 2025

Jasper Therapeutics’ (JSPR) Buy Rating Reiterated at HC Wainwright - Defense World

Mar 14, 2025
pulisher
Mar 11, 2025

Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics - TipRanks

Mar 11, 2025
pulisher
Mar 07, 2025

FY2025 EPS Estimates for JSPR Raised by Cantor Fitzgerald - Defense World

Mar 07, 2025
pulisher
Mar 03, 2025

Oppenheimer maintains $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada

Mar 03, 2025
pulisher
Mar 03, 2025

Stifel maintains Buy rating, $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada

Mar 03, 2025
pulisher
Mar 03, 2025

Positive Outlook for Jasper Therapeutics: Buy Rating Affirmed on Promising BEACON Study Data and Strategic Milestones - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Jasper Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Equities Analysts Set Expectations for JSPR Q1 Earnings - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study - MSN

Mar 02, 2025
pulisher
Mar 02, 2025

JSPRJasper Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Mar 02, 2025
pulisher
Mar 01, 2025

Jasper Therapeutics Presents Updated Clinical Data on Briquilimab at AAAAI 2025 Annual Meeting - Nasdaq

Mar 01, 2025
pulisher
Mar 01, 2025

Jasper Therapeutics Presents Clinical and Preclinical - GlobeNewswire

Mar 01, 2025
pulisher
Mar 01, 2025

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - Yahoo Finance UK

Mar 01, 2025
pulisher
Mar 01, 2025

Can Jasper Therapeutics' Briquilimab Transform Chronic Urticaria Treatment? New Clinical Data Revealed - Stock Titan

Mar 01, 2025
pulisher
Feb 28, 2025

Promising Outlook for Jasper Therapeutics: Buy Rating Backed by Briquilimab’s Clinical Progress and Financial Stability - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Jasper Therapeutics Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

Jasper Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

Jasper Therapeutics to present briquilimab study at AAD Meeting - Investing.com India

Feb 28, 2025
pulisher
Feb 28, 2025

Jasper Therapeutics to present briquilimab study at AAD Meeting By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Jasper Therapeutics Announces Late-Breaking Briquilimab - GlobeNewswire

Feb 28, 2025
pulisher
Feb 28, 2025

Can Jasper's Briquilimab Data for Chronic Urticaria Transform Treatment Outcomes? - StockTitan

Feb 28, 2025
pulisher
Feb 28, 2025

Jasper Therapeutics Reports Promising Clinical Progress - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Jasper Therapeutics: Strategic Advancements and Promising Clinical Efficacy Drive Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Promising Data from Jasper Therapeutics’ BEACON and SPOTLIGHT Studies Justify Buy Rating for Briquilimab - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Jasper Therapeutics reports Q4 EPS ($1.62), consensus ($1.23) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Feb 27, 2025
pulisher
Feb 26, 2025

Earnings To Watch: Life Time (LTH) Reports Q4 Results Tomorrow - The Globe and Mail

Feb 26, 2025
pulisher
Feb 25, 2025

Jasper Therapeutics to Present at Upcoming March Investor Conferences - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Jasper Therapeutics Sets March Conference Circuit to Showcase Mast Cell Disease Breakthroughs - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Jasper Therapeutics’ SWOT analysis: briquilimab’s potential reshapes CSU stock outlook - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes CSU stock outlook - Investing.com India

Feb 25, 2025
pulisher
Feb 23, 2025

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $64.44 Consensus PT from Analysts - Defense World

Feb 23, 2025
pulisher
Feb 21, 2025

Learn to Evaluate (JSPR) using the Charts - Stock Traders Daily

Feb 21, 2025
pulisher
Feb 20, 2025

Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.

Feb 20, 2025
pulisher
Feb 19, 2025

What To Expect From RE/MAX’s (RMAX) Q4 Earnings - The Globe and Mail

Feb 19, 2025
pulisher
Feb 18, 2025

Jasper Therapeutics stock holds $70 target at JMP Securities By Investing.com - Investing.com Canada

Feb 18, 2025
pulisher
Feb 18, 2025

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Down 11.1% in January - Defense World

Feb 18, 2025
pulisher
Feb 15, 2025

Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from Analysts at UBS Group - MarketBeat

Feb 15, 2025
pulisher
Feb 13, 2025

UBS Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation - Nasdaq

Feb 13, 2025
pulisher
Feb 12, 2025

JSPR stock touches 52-week low at $5.22 amid market challenges - Investing.com Nigeria

Feb 12, 2025
pulisher
Feb 10, 2025

Objective long/short (JSPR) Report - Stock Traders Daily

Feb 10, 2025
pulisher
Feb 10, 2025

Jasper Therapeutics Announces Briquilimab Presentations at - GlobeNewswire

Feb 10, 2025
pulisher
Feb 10, 2025

Jasper Therapeutics Announces Presentations of Briquilimab Data at AAAAI 2025 Annual Meeting - Nasdaq

Feb 10, 2025
pulisher
Feb 10, 2025

Jasper's Briquilimab Takes Center Stage: 6 Key Data Presentations to Reveal Treatment Breakthrough at AAAAI 2025 - Stock Titan

Feb 10, 2025
pulisher
Feb 06, 2025

JSPR’s Stock Market Labyrinth: Navigating 2023’s Gains and Declines - The InvestChronicle

Feb 06, 2025
pulisher
Feb 06, 2025

Selling Buzz: Jasper Therapeutics Inc [JSPR] Chief Operating Officer Mahal Jeetinder Singh sells 900 shares of the company – Knox Daily - Knox Daily

Feb 06, 2025
pulisher
Feb 05, 2025

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference - GlobeNewswire

Feb 05, 2025
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
자본화:     |  볼륨(24시간):